Photocure

Less than 1K followers

PHO

Oslo Børs

Biotechnology & Pharmaceuticals

Health Care

Overview

Investor consensus

Photocure is a medical technology company. The company specializes in photodynamic technology solutions. The solutions are used to treat diseases that cause bladder cancer and HPV. The main markets are dermatology and oncology, where the products are used by hospitals and research institutes worldwide. The company was founded in 1993 and is headquartered in Oslo, Norway.

Market cap

-

Turnover

-

Revenue

532.58M

EBIT %

-0.14 %

P/E

-

Dividend yield-%

-

Financial calendar

25/6

2026

General meeting '26

29/7

2026

Interim report Q2'26

28/10

2026

Interim report Q3'26

All

Press releases

ShowingAll content types

Regulatory press release5/18/2026, 3:00 PM

AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study

Press release5/18/2026, 3:00 PM

AUA 2026: new studies demonstrated Blue Light Cystoscopy benefits in high-risk NMIBC management and cost comparison study

Regulatory press release5/7/2026, 5:00 AM

Photocure ASA: Results for the first quarter of 2026

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Regulatory press release5/7/2026, 5:00 AM

Photocure ASA: Results for the first quarter of 2026

Regulatory press release5/4/2026, 6:00 AM

New health economic methodology published: comparing cost-effectiveness of BLC versus NBI imaging technology in bladder cancer

Press release5/4/2026, 6:00 AM

Photocure: New health economic methodology published: comparing cost-effectiveness of BLC versus NBI imaging technology in bladder cancer

Regulatory press release4/30/2026, 7:00 AM

Photocure ASA: Invitation to presentation of first quarter 2026 financial results

Press release4/30/2026, 7:00 AM

Photocure ASA: Invitation to presentation of first quarter 2026 financial results

Regulatory press release4/27/2026, 7:00 AM

Photocure ASA: Annual Report 2025

Regulatory press release4/27/2026, 7:00 AM

Photocure ASA: Annual Report 2025

Regulatory press release4/20/2026, 2:31 PM

Photocure ASA: Update on milestone payments from Asieris Pharmaceuticals

Regulatory press release4/20/2026, 2:31 PM

Photocure ASA: Update on milestone payments from Asieris Pharmaceuticals

Regulatory press release4/13/2026, 2:20 PM

PHO: Financial calendar

Regulatory press release4/13/2026, 6:30 AM

Photocure ASA: Update on Regulatory Classification for OAY Equipment

Regulatory press release4/13/2026, 6:30 AM

Photocure ASA: Update on Regulatory Classification for OAY Equipment

Regulatory press release3/16/2026, 4:00 PM

Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway

Press release3/16/2026, 4:00 PM

Photocure: Trials in Progress presented at the European Association of Urology (EAU) 2026 congress aim to enable a more personalized bladder cancer care pathway

Regulatory press release3/3/2026, 9:35 AM

Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Press release3/3/2026, 9:34 AM

Photocure: Asieris: CEVIRA Approved in China as First-in-Class Non-Invasive Therapy for Cervical Precancerous Lesions

Press release2/27/2026, 9:17 AM

Photocure partner Asieris announces that EMA has accepted Marketing Authorization Application for CEVIRA in Europe

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.